Alchemyca Biotech | $2,500,000 | (Nov 22, 2024)
OneCell Diagnostics Inc. | $16,000,000 | (Nov 22, 2024)
Iontra Inc | $45,000,000 | (Nov 22, 2024)
4baseCare
India
- Bengaluru, Karnataka
- 13/08/2024
- Series A
- $6,000,000
4baseCare, an Illumina-backed Company* headquartered in Singapore, is engaged in developing cutting-edge Precision Oncology Solutions using Advanced Genomics and Next-Gen digital health technology.
Taking into consideration that the clinical outcome could significantly vary across different populations, we have developed a unique set of indigenous comprehensive cancer gene panels that enables oncologists to choose the optimal precision therapies for their patients.
Our coveted genomic testing portfolio assesses the tumour genomic alterations by NGS from Tissue or Liquid biopsy for Somatic Mutation Analysis and Germline Mutation Testing for Hereditary and Familial Cancer from peripheral blood to personalize patient care in Oncology.
*Part of Illumina Accelerator 10th Cycle
- Industry Biotechnology Research
- Website https://4basecare.com/
- LinkedIn https://www.linkedin.com/company/4basecare/
Related People
Hitesh GoswamiCo Founder
India -
Bengaluru, Karnataka
Hitesh is a co-founder and CEO of 4basecare. He oversees operations across complete business cycle - Clinical oncology, Research and Development, Collaborations, Genomics, Technology, Business development, Sales operations and other Corporate functions.
Hitesh is also co-founder of leading Genome “IT” company, Bionivid Technology (founded in 2011) which provides niche IT solutions to handle Genomics BIG DATA challenges which includes analytics, data processing, storage and training / education and awareness in the domain of Genomics and Genome Informatics.
Hitesh has 12+ years of experience in pharma drug discovery and Genomics. Prior to his entrepreneur journey, Hitesh was part of High throughput screening and drug discovery team at Piramal Lifesciences (then called Nicholas Piramal Research Centre) working on identifying novel small molecules and formulations for their efficacy in therapeutic areas like Cancer, Inflammation and Diabetes.
Enveda | $130,000,000 | (Nov 22, 2024)
Shinami | $5,645,000 | (Nov 22, 2024)
DANNCE.ai | $2,600,000 | (Nov 22, 2024)
Trustero | $10,000,000 | (Nov 22, 2024)
Dote | $1,447,585 | (Nov 22, 2024)
CredFlow | $3,700,000 | (Nov 22, 2024)
Lighthouse (UK) | $370,000,000 | (Nov 22, 2024)
Faircraft | $15,800,000 | (Nov 22, 2024)
Clean Skin Club | $32,000,000 | (Nov 22, 2024)